ArticleJournal of gastroenterology2026

Impact of TOPAZ-1 eligibility on the survival benefit of durvalumab plus gemcitabine-cisplatin in advanced biliary tract cancer: a multicenter real-world study.

Hisashi Kosaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.